Two serums can name the same ingredient and differ completely. With NMN, the difference is the formula: how it is designed, stabilised and made.
English · Français · 한국어 · PDF version
Published research shows that nicotinamide mononucleotide (NMN) can raise NAD⁺ in human skin cells and influence pathways tied to mitochondrial function, cellular senescence and skin repair. NMN is also highly hydrophilic, formulation-sensitive and difficult to deliver through skin. The value of topical NMN therefore does not come from adding the ingredient. It comes from how the finished formula is designed, stabilised and delivered.
Because an ingredient list is a record of the batch, not of the skin. An INCI listing records that NMN was added at manufacture. It does not record how much survives to the point of use, or whether any of it reaches living skin.
Both of those are formulation outcomes, and no label distinguishes them. Two products naming the same molecule can sit at opposite ends of that path.
Two findings, both from laboratory models. In human skin cells NMN behaves differently from other NAD⁺ precursors, and in a skin-permeation model it reached the region where it would matter. Neither is a trial of a finished product on human skin.
In human skin fibroblasts, NMN produced a distinct gene-expression profile from nicotinamide riboside and nicotinamide, raised NAD⁺, activated sirtuin and autophagy pathways and suppressed senescence.1
In a skin-permeation model NMN crossed the membrane into the papillary dermis region, and NMN-treated fibroblasts increased Type I collagen production.2
What is not yet supported is stated in full in the evidence brief: its literature search located no published randomised controlled trial of topical NMN on human facial skin.
Three things at once. Three independent research groups describe NMN's topical liability in near-identical terms: high hydrophilicity, poor skin permeability, limited stability.3,4,5
NMN is highly water-soluble, and it degrades in solution.
Free NMN does not penetrate well, which is why researchers build carriers for it.
Stability belongs to the matrix, not to the molecule. Change what NMN is carried in and the result changes with it.
That is why the literature is full of liposomes, nanogels and coated vesicles built to carry it.
In our own lab in South Surrey, BC, with no contract manufacturing. That makes every variable below a decision we make and can account for. There are six.
Three clients were documented on standardised clinical imaging over two to six months. These are observational outcomes of complete protocols, not controlled trials, and each is reported with what it does not show.
The three case studies cover mature, sun-exposed skin over three months, blemish-prone skin with a compromised barrier over two months, and marks and uneven tone over six months. None of them shows that NMN, or any single ingredient, caused the change. Individual results vary.
In the topical NMN evidence brief: all twelve references with DOI links, the counter-evidence, and the limits stated plainly. The five papers cited on this page are listed here. Literature from PubMed.
This page makes no medical claim and describes no product as a treatment for any condition. It is educational and does not replace medical diagnosis or treatment. Case documentation describes individual observational outcomes from one practice; results are not attributable to any single product or ingredient and individual results vary.
When skin gets complicated, formulation matters.